Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
AstraZeneca plc (ADR) - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
AZN
Nasdaq
2834
https://www.astrazeneca.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for AstraZeneca plc (ADR)
20 Countries with the Highest Cancer Survival Rates in the World
- Apr 19th, 2024 6:05 pm
Astrazeneca (AZN) Could Be a Great Choice
- Apr 18th, 2024 3:45 pm
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
- Apr 16th, 2024 11:00 am
4 Exceptional Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
- Apr 14th, 2024 8:41 am
AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids
- Apr 12th, 2024 2:33 pm
Pharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News
- Apr 12th, 2024 1:22 pm
Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know
- Apr 11th, 2024 10:15 pm
AstraZeneca hit by investor backlash over chief Pascal Soriot’s £19m pay deal
- Apr 11th, 2024 5:53 pm
World risks ‘tepid Twenties’ as debt levels and inflation soar, warns IMF
- Apr 11th, 2024 5:32 pm
AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition
- Apr 11th, 2024 5:01 pm
UPDATE 2-AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition
- Apr 11th, 2024 4:53 pm
FASENRA approved for treatment of children aged 6 to 11 with severe asthma
- Apr 11th, 2024 11:00 am
Trending tickers: Darktrace, AstraZeneca, Persimmon, Bitcoin
- Apr 11th, 2024 10:36 am
CORRECTED-UPDATE 1-European shares dip ahead of ECB policy decision
- Apr 11th, 2024 9:16 am
AstraZeneca promises dividend rise ahead of vote on chief’s £18.7m pay deal
- Apr 11th, 2024 8:08 am
AstraZeneca announces dividend hike ahead of CEO pay vote
- Apr 11th, 2024 6:30 am
Major investors say AstraZeneca boss is ‘massively underpaid’ on $21.5 million salary, despite earning more than double Novo Nordisk’s CEO
- Apr 10th, 2024 10:10 am
ZTS, EXAS, AZN: Which Biotech Stock Is the Better Buy?
- Apr 10th, 2024 4:00 am
UK pharma companies told to make fewer drugs in draft net zero guidelines
- Apr 9th, 2024 5:00 am
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
- Apr 8th, 2024 4:34 pm
Scroll